GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » IM Cannabis Corp (XCNQ:IMCC) » Definitions » ROCE %

IM Cannabis (XCNQ:IMCC) ROCE % : -169.14% (As of Mar. 2024)


View and export this data going back to 1980. Start your Free Trial

What is IM Cannabis ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IM Cannabis's annualized ROCE % for the quarter that ended in Mar. 2024 was -169.14%.


IM Cannabis ROCE % Historical Data

The historical data trend for IM Cannabis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IM Cannabis ROCE % Chart

IM Cannabis Annual Data
Trend Apr13 Apr14 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -50.38 0.38 -18.32 -27.00

IM Cannabis Quarterly Data
Apr19 Jul19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.21 -24.00 -107.83 -69.90 -169.14

IM Cannabis ROCE % Calculation

IM Cannabis's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-5.786/( ( (60.676 - 33.819) + (48.813 - 32.808) )/ 2 )
=-5.786/( (26.857+16.005)/ 2 )
=-5.786/21.431
=-27.00 %

IM Cannabis's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-22.52/( ( (48.813 - 32.808) + (41.109 - 30.485) )/ 2 )
=-22.52/( ( 16.005 + 10.624 )/ 2 )
=-22.52/13.3145
=-169.14 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IM Cannabis  (XCNQ:IMCC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


IM Cannabis ROCE % Related Terms

Thank you for viewing the detailed overview of IM Cannabis's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


IM Cannabis (XCNQ:IMCC) Business Description

Traded in Other Exchanges
Address
Central District, Kibbutz Glil Yam, ISR, 4690500
IM Cannabis Corp is a Canada-based international medical cannabis company. It offers government-licensed cannabis products, from generic to GMP-certified and pharmaceutical-grade, for both wholesale and retail clients. The majority of its revenues are generated from sales of medical cannabis products to customers in Israel and recreational cannabis in Canada. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
Executives
Rafael Gabay 10% Security Holder